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Abstract
Vaccination against human papillomavirus (HPV) has been introduced as a public
health initiative in many countries, including Denmark since October 2008. It is
important to monitor postimplementation effectiveness of HPV-vaccination at the
population-level. We studied HPV-prevalence after first invitation to screening at
age 23 years in women offered the quadrivalent HPV-vaccine at the age of 14 years.
Randomly selected screening samples from women born in 1994 in four out of five
Danish regions were subjected to analysis for HPV in addition to routine cytology.
Cobas4800 was used in all participating pathology departments. Data from a Danish
prevaccination cross-sectional study using Hybrid Capture 2, and a Danish split-sam-
ple study using Cobas4800 were used for comparison. In the period from February
2017 to April 2019, 6233 screening samples from women born in 1994 were
selected for HPV-analysis; 27 samples had no HPV-test and 3 samples had no
HPV-diagnosis, leaving 6203 samples with an HPV-diagnosis. Prevalence of any
high-risk (HR) HPV was 35%; only 0.9% were positive for vaccine HPV types 16/18
while the remaining 34% were positive for other HR HPV. When comparing with
prevaccination prevalence data, HPV-16/18 decreased by 95%; RR = 0.05 (95% CI
0.04-0.06), while other HR HPV remained fairly constant; RR = 0.88 (95% CI 0.82-
0.94) and RR = 0.95 (95% CI 0.88-1.03), respectively. One-third of women vaccinated
as girls with the quadrivalent HPV-vaccine were HR HPV-positive at time of first invi-
tation to screening. Vaccine HPV-types 16 and 18 were almost eliminated, while the
prevalence of nonvaccine HR HPV-types remained constant.
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1 | INTRODUCTION
Persistent infection with human papillomavirus (HPV) is a necessary
step in cervical cancer pathogenesis.1 All three HPV-vaccines protect
against the high-risk (HR) types 16 and 18, accounting for 70% of cer-
vical cancers.2 The nine-valent HPV-vaccine protects against an addi-
tional five HR HPV-types (31, 33, 45, 52 and 58), and is expected to
prevent 90% of cervical cancers.3
HPV-vaccination is widely disseminated in high-income countries
and vaccinated women have been shown systematically to have a
lower prevalence of HPV-16 and HPV-18 than nonvaccinated
women; indicating effectiveness of the vaccine in real-life.4 Many
countries have furthermore changed from cytology to HPV-testing in
primary cervical screening. Data on prevalence of HPV-infection at
screening age in birth cohorts HPV-vaccinated as girls are, however,
still scarce. Insight into HPV-prevalence after vaccination is crucial
from a public health point of view as quality assurance of the HPV
immunization programs, and for determining the future combination
of HPV-vaccination and screening in control of cervical cancer.
Here we report on the prevalence of HPV-infection at screening
in a birth cohort offered the quadrivalent HPV-vaccination at the age
of 14 years, and personally invited to screening with cytology at the
age of 23 years in the Danish national screening program. For com-
parison, we used data on HPV-prevalence in young Danish women
collected prior to the implementation of HPV-vaccination.5,6
2 | MATERIALS AND METHODS
2.1 | Cervical cancer prevention in Denmark
In October 2008, 13- to 15-year-old girls born in 1993 to 1995 were
offered free HPV-vaccination, and since January 2009 HPV-vaccination
has been offered to 12-year-old girls.7 The quadrivalent HPV-vaccine
was used until 2015, and the bivalent HPV-vaccine until 2017, when it
was replaced by the nine-valent HPV-vaccine.8,9
Cervical screening in Denmark targets women aged 23 to
64 years. At the age of 23 years, all women are personally invited to
have a sample taken by their general practitioner, unless they are reg-
istered already with a cytology sample, which is the case for a minor-
ity only. At age 23 to 49 screening is offered every third year, and at
age 50 to 64 every fifth year.7,10 All laboratories in Denmark use liq-
uid-based cytology (LBC). In 2020, primary HPV-DNA testing will be
piloted for half of women aged 30 to 59 years, while LBC screening
will be retained for the other half and for all women aged 23 to
29 years. Women aged 60 to 64 are offered an HPV-DNA exit test.11
2.2 | Study population
Residual material from cervical screening samples was analyzed for
HPV as part of a method study on the possible use of primary HPV-
testing in young, HPV-vaccinated women.12 The study population
included a random sample of women born in 1994; offered quadriva-
lent HPV-vaccination at the age of 14 years in 2008, and invited for
cervical cytology screening, when they turned 23 years in 2017.
According to national vaccine surveillance, 83% of women born in
1994 had at least one HPV-vaccine dose.13
2.3 | Procedures
Pathology departments responsible for cervical screening in three and
a half out of five Danish regions, covering half of Denmark, were
involved in the study (Aalborg, Randers, Esbjerg, Soenderborg and
Naestved) which started in February 2017. The selection of samples
for HPV-analysis was based on randomization of women born in 1994
present in Denmark in January 2017, so that samples from half of the
women would be subjected to HPV-analysis in addition to the routine
cytology examination. At the scanning of the bar code of a newly
received sample at the pathology department, a “pop-up” message
told that (a) the sample should be included in the study, and (b)
whether an HPV-test should be performed or not. Cobas 4800 HPV-
DNA test (Roche Diagnostics, Indianapolis, Indiana), already in clinical
use in the participating laboratories, was used according to the manu-
facture's guidelines. Samples were clinician collected in SurePath liq-
uid-based medium (BD, Franklin Lakes, New Jersey) with the
detachable head of the device placed in a vial containing preservative
fluid. SurePath collected samples were handled in accordance with
the manufacturer's protocols. Residual LBC material was utilized for
HPV-DNA testing. Then, 500 μL of diluted material were transferred
to test tubes for analysis. Our study was embedded in the routine
work at the labs, and Cobas4800 was used in the labs in advance for
triage of ASCUS in women aged 30 and above. Before HPV-testing,
most labs performed pretreatment in accordance with the manufac-
turer's protocol. Cobas 4800 is based on real-time PCR and can detect
14 HR HPV-types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66
and 68) with four channels; HPV-16, HPV-18, a joined channel for the
What's new?
Vaccination against human papillomavirus (HPV) has been
introduced as a public health initiative in many countries.
However, data on HPV infection prevalence at screening age
in HPV-vaccinated birth cohorts remain scarce. This study
found that HPV-16 and 18 were almost eliminated in a pop-
ulation aged 23-24 years where 92% of women received
quadrivalent HPV vaccination at age 14. Prevalence of HPV
16 and 18 was lower in non-vaccinated women than in
previous birth cohorts not offered HPV-vaccination. None-
theless, one third of vaccinated women were positive for
high-risk HPV other than 16/18, with potential implications
for cervical cancer prevention and screening programs.
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remaining 12 HR HPV-types henceforth called “other HPV-types”,
and a β-globin channel as control.14
2.4 | Prevaccine data used for comparison
In 2002 to 2005, a Danish cross-sectional study examined HPV-
prevalence in a screened population of 40 382 women aged 14 to
95 years before implementation of HPV-vaccination.5 The study took
place in the Capital Region of Denmark. In the age group 20 to
23 years, 2045 screening samples were analyzed for HPV using
Hybrid Capture 2 (HC2) and Line Probe Array for genotyping of HC2-
positive samples5 (Louise Thomsen and Susanne Krüger Kjær, per-
sonal communication, March 5, 2020). In 2011, a Danish split-sample
study, Horizon, was conducted in the Capital Region of Denmark.6 In
the study, 5072 cervical screening samples were tested for HPV using
different assays. The study included 1522 cervical samples from
women aged 23-29 years tested with Cobas48006 (Jesper Bonde,
personal communication, February 21, 2020). We used data from
these two studies for comparison with our findings. Daily smoking in
girls had decreased over time, but otherwise, the three study bases
were fairly equal in demographics and behavior (Table S1).
2.5 | Statistical analysis
Only the first screening sample for a given woman was included in the
analysis. We assessed prevalence of any HR HPV, and of the following
subgroups: (a) any 14 HR HPV; (b) all HPV-16/18 including samples
also with other types; (c) all HPV-16 including samples also with other
F IGURE 1 Study population,
allocation to HPV-testing and the
presence of test results
3448 LYNGE ET AL.
types, but excluding HPV-18; (d) all HPV-18 including samples also
with other types, but excluding HPV-16; (e) all 12 HR HPV Other
including also samples with HPV-16 or HPV-18; and (f) HPV-negative.
Henceforth HR HPV is referred to as HPV. We did not have a specific
code for unsatisfactory HPV-test, but estimated that this was an issue
for less than 20 samples. Prevalence proportions and relative risks
(RR), together with corresponding 95% confidence intervals (CI), have
been calculated using the binomial exact method and Wald method,
respectively. Calculations and plots have been made using SAS statis-
tical software version 9.4 and R version 3.6.2, with ggplot2 package.
3 | RESULTS
Out of 18 924 women born in 1994 and living in the study area,15
12 277 women; 65%, participated in the screening and were assigned
a project code between February 1, 2017, and April 2019 (Figure 1).
Of these, 6220 women were allocated to have an HPV-test in addi-
tion to the routine cytology, 6065 women were allocated to cytology
alone, while allocation missed for seven women. An additional 13
women had a project HPV-test without a project code; they were
included in the HPV-group increasing the number to 6233 women; of
whom 27 women did not have a HPV-test recorded, and three
women did not have a proper HPV-diagnosis, leaving 6203 women to
be included in the study (Figure 1).
Of the 6203 samples with an HPV-diagnosis, 35% (95% CI 33.7-
36.1) were HPV-positive (Table 1). Only 0.9% (95% CI 0.7-1.1) of
women were infected with the vaccine types HPV-16 or 18 with the
majority positive for HPV-16 but not for HPV-18, 0.7% (95% CI 0.7-
1.1), and 0.2% (95% CI 0.5-1.0) positive for HPV-18 but not for HPV-
16. No woman was positive for both HPV-16 and HPV-18. In total,
34.4% (95% CI 33.2-35.6) of women were positive on the channel in
the Cobas4800 assay measuring infection with at least one of the
other 12 HPV-types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68).
TABLE 1 Prevalence of HR HPV in 6203 cervical screening samples from women born in 1994, from 2045 women aged 20 to 23 and
screened in 2002 to 20055, and from 1522 women aged 23 to 29 and screened in 20116
Study Present study Kjær et al, 20145 Preisler et al, 20136
Data collected 2017-2019 2002-2005 2011
Women aged, years 23-24 20-23 23-29
Women born 1994 App. 1978-1985 App. 1981-1989
HPV-vaccination 1994: Offered at age 14 1978-1984: not offered
1985: offered at age 26/27
1981-1984: not offered
1985-1989: offered at
age 23/24-26/27
Sample media Sure Path Sure Path Sure Path
HPV-assay Cobas4800 HC2, positive genotyped with LiPA Cobas4800
HPV-diagnosis Numbera Prevalencea 95% CI Numbera Prevalencea 95% CI Numbera Prevalencea 95% CI
Number studied 6203 — — 2045 — — 1522 — —
Any 14 HR HPV-positive 2164 34.9% 33.7-36.1 [940] 46.0% 43.8-48.2 654 43.0% 40.5-45.5
All HPV-16/18 (including samples
with other HR-types)
54 0.9% 0.7-1.1 [380] [18.6%] [16.9-20.3] 253 16.6% 14.8-18.6
All HPV-16 (including samples with
HR-types other than 18)
45 0.7% 0.5-1.0 [241] 11.8% 10.4-13.3 185 12.2% 10.6-13.9
All HPV-18 (including samples with
HR-types other than 16)
9 0.2% 0.1-0.3 [100] 4.9% 4.0-5.9 55 3.6% 2.7-4.7
All 12 HPV-Other (including samples
with HPV-16/18)
2132 34.4% 33.2-35.6 801 39.2% 37.0-41.3 549 36.1% 33.7-38.5
HPV-Negative 4039 65.1% 63.9-66.3 [1105] [54.0%] [51.6-56.2] 868 57.0% 54.5-59.5
Abbreviations: CI, confidence interval; NR, not reported; RR, relative risk; [ ] Calculated by authors.
aCategories are partly overlapping.
F IGURE 2 Comparison of HPV-prevalence data in the era before
and after HPV-vaccination
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In the first comparison study5 with samples collected from 2002
to 2005, 46% (95% CI 43.8-48.2) of women aged 20 to 23 years were
HPV-positive, with 18.6% being positive for the vaccine types HPV-
16 or HPV-18 alone or in combination with other HPV-types. Positiv-
ity for HPV16 but not for 18 was found in 11.8% (95% CI 10.4-13.3)
of women, and positivity for HPV18 but not for 16 was found in 4.9%
(95% CI 4.0-5.9) of women. The proportion of women positive for
other HPV-types, including those positive for HPV-16/18, was 39.2%
(95% CI 37.0-41.3).
In the second comparison study with samples collected in 2011,
43% (95% CI 40.5-45.5) of women aged 23 to 29 years were HPV-posi-
tive; with 16.6% (95% CI 14.8-18.6) being positive for at least one of the
vaccine types HPV-16 and HPV-18. In total, 36.1% (95% CI 33.7-38.5)
of the women were infected with at least one of the other HPV-types.
Comparing our findings with the 2002 to 2005 data, the preva-
lence of HPV decreased from 46% to 34.9%, RR = 0.76 (95% CI 0.72-
0.80) from before to after HPV-vaccination. The prevalence of vac-
cine types HPV-16 and HPV-18 decreased dramatically by 95%, from
18.6% to 0.9%, RR = 0.05 (95% CI 0.04-0.06). Comparing our findings
with the 2011 data, the prevalence of HPV decreased from 43% to
34.9%, RR = 0.81 (95% CI 0.76-0.87). Also here, the prevalence of the
vaccine types HPV-16 and HPV-18 decreased by 95%, from 16.6% to
0.9%, RR = 0.05 (95% CI 0.04-0.07). In contrast, the prevalence of the
other HPV-types remained fairly constant changing from 39.2% to
34.4% in comparison with the 2020 to 2005 data, RR 0.88 (95% CI
0.82-0.94), and from 36.1% and 34.4% in comparison with the 2011
data, RR = 0.95 (95% CI 0.88-1.03, Figure 2).
Vaccination coverage was 92% for at least one dose of the quad-
rivalent HPV-vaccine in the cohort of 6203 women in the present
study, of whom 97% were vaccinated at age 15 years at the latest.
While the prevalence of the vaccine HPV types 16 and 18 was 0.4%
in vaccinated women it was 6.6% in nonvaccinated women, RR = 0.05
(95% CI 0.03-0.09; Table 2). The prevalence of other HPV-types was
slightly higher in vaccinated than in nonvaccinated women; 34.8% vs
30.1%, RR = 1.15 (95% CI 1.01-1.32).
4 | DISCUSSION
4.1 | Main findings
The prevalence of high-risk HPV-infection around the age of 23 years,
when women in Denmark are first invited to screening, was 35% in
the 1994 birth cohort where almost all had been HPV-vaccinated as
girls. In comparison, 43% to 46% were HPV-positive in birth cohorts
where no one had been HPV-vaccinated as girls. Infection with the
vaccine HPV types 16 and 18 was almost eliminated in the vaccinated
cohort, while it constituted an infection burden of 17% to 19% in the
nonvaccinated cohorts.
In the 1994 birth cohort, a small number, less than half a per-
cent, of the actually vaccinated women were positive for HPV-16
or HPV-18. It should be stressed that these cases cannot be con-
sidered as vaccine breakthrough infections, as not all the girls were
HPV-naïve at the time of vaccination. The HPV-16 and HPV-18
prevalence in actually nonvaccinated women born in 1994 was less
than half of that found in the comparison groups not offered child-
hood HPV-vaccination. This could indicate a herd immunity effect;
which could be enhanced also by the fact that all birth cohorts
born from 1993 onwards have been offered childhood HPV-
vaccination.
Our data indicated that vaccination with the quadrivalent HPV-
vaccine affected the risk of infection with high-risk HPV-types other
than 16 and 18 only slightly. The proportion of women testing posi-
tive on other high-risk HPV-types was almost the same in the 1994
birth cohort as in the older birth cohorts not HPV-vaccinated as girls.
4.2 | Findings in perspective of other studies
In a recently published meta-analysis on real-life impact of HPV-vacci-
nation,4 the prevalence of HPV-16 and HPV-18 was found to have
decreased by 83% 5 to 8 years after vaccination among girls aged 13
to 19 years, and by 66% among women aged 20 to 24 years. The end-
points in the meta-analysis were estimated from different types of
studies. In our cohort study, where we had a longer follow-up of 8 to
10 years after HPV-vaccination, which took place at the age of 14 to
15 years, we found an even larger decrease of 95% in the prevalence
of HPV-16 and HPV-18. The meta-analysis indicated an increase in
the prevalence of the nonvaccine HPV-types. For this finding, three
possible explanations were suggested: (a) a change in the background
risk of HPV-infection due to changes in sexual behavior; (b)
unmasking, because HPV-16 and HPV-18 could previously have
masked detection of these other HPV-types; and (c) type replacement
where other HPV types will fill the niche left after HPV-16 and
HPV-18.
TABLE 2 Prevalence of HPV in 6203 cervical screening samples from women born in 1994 stratified by HPV-vaccination status
Vaccinated (%) Nonvaccinated (%) RR (95% CI)
Number of women 5685 518 NR
HPV-positive 1987 (34.9%) 177 (34.2%) 1.02 (0.90-1.16)
HPV-16/18 (including samples with other HPV-types) 20 (0.4%) 34 (6.6%) 0.05 (0.03-0.09)
HPV-other (including samples with HPV-16/18) 1976 (34.8%) 156 (30.1%) 1.15 (1.01-1.32)
HPV-negative 3698 (65.1) 341 (65.8) 0.99 (0.93-1.05)
Abbreviations: CI, confidence interval; NR not relevant; RR, relative risk.
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In contrast to changes reported from for instance the UK,16 sex-
ual habits have been fairly stable in Denmark, where the average age
at first intercourse has remained at the age of 16 years,17,18 and the
median number of sexual partners for women aged 18 to 24 years
was 4 in 2005 and 5 in 2012.17 Changes in sexual behavior are there-
fore not likely to have biased the comparison of HPV-data between
for the generations of young women screened in 2002 to 2005, 2011
and 2017 to 2019, respectively.
We used Cobas4800 for HPV-testing. In the studies we used for
comparison, the samples were tested on HC25 and Cobas4800,6
respectively, but due to cross-reaction with HPV 66 in HC2, the two
assays essentially detect the same 14 HPV-types. In the Danish split-
sample study,6 the HPV-positivity rate for women aged 23 to
29 years was 33% with HC2 and 43% with Cobas4800. Changes from
use of the first generation HC2-assay to the second generation
Cobas4800 assay could then have contributed to the increase in non-
vaccine HPV-types indicated in the meta-analysis.4 The fact that the
HPV-positivity rate was slightly higher in our comparison study using
the HC2-assay than in the one using the Cobas4800-assay can proba-
bly be ascribed to the fact that the first study group was slightly youn-
ger than the second, 20 to 23 years and 23 to 29 years, respectively.
For the comparison of positivity on other high-risk HPV types than 16
and 18, it should be taken into account that while this group in our,
and the 2011 data, was identified based on the other-HPV-signal in
the Cobas4800, it was in the 2002 to 2005 data identified based on
HC2-positivity in combination with the Line Probe Array for
genotyping.
The stability in the proportion of women positive for the non-
vaccine high-risk HPV-types could indicate that neither cross-protec-
tion nor unmasking, or type-replacement took place. Due to the
limitation in the Cobas4800 assay, we were, however, not able to
reveal possible opposite changes behind the overall stability.
4.3 | Strengths and limitations
This study was population-based including randomly selected women
living in well-defined parts of Denmark, and with a cervical sample
taken after first invitation to screening at Age 23 years. The screening
coverage was 65%. All samples were tested with Cobas4800. The
women had been offered HPV-vaccination at age 14 years, and the
vaccination coverage in the screened women was 92%. Between 8
and 10 years had passed between time of vaccination and time of
screening. Due to partial genotyping, it was not possible to examine
possible cross-protection and/or possible unmasking and/or type
replacement.
HPV-vaccination coverage was quite high in the study, and practi-
cally all women were vaccinated at young age. While we can assume
that the majority of vaccinated women were HPV-naïve at the time of
vaccination, this will not have been the case for all, as 24% of girls in
this generation reported to have been sexually active at the age of
14 years.19
4.4 | Clinical implications
HPV-16 and HPV-18 have been found to be responsible for 70% of
cervical cancers. The fact that we found HPV-16 and HPV-18 to be
almost eliminated at age 23 to 24 years in women HPV-vaccinated
with the quadrivalent vaccine at age 14 to 15 years, therefore,
pointed to a considerably improved protection against cervical cancer
in women HPV-vaccinated as girls. Nevertheless, still, 35% of the
women were high-risk HPV-positive strongly indicating that primary
HPV-screening of women in this age group would have to be com-
bined with triage to avoid referral to colposcopy of too many women
with no underlying histological lesion. In 2017, Denmark changed to
the nine-valent HPV-vaccine, which provides a better protection
against cervical cancer than the quadrivalent vaccine, and the HPV-
positivity rate in young women is therefore expected to decrease
when these younger birth cohorts will reach screening age.
5 | CONCLUSION
The prevalence of the vaccine HPV-types 16 and 18 was less than 1%
when in young, Danish women offered quadrivalent HPV-vaccination
as girls attended cervical screening at the age of 23 to 24 years. This
corresponded to a 95% decrease in comparison with the prevalence
from the prevaccination era. Despite this impressive reduction, 35%
of women were still HPV-positive.
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